CO2019001625A2 - Compuestos de captura de aldehído y usos de los mismos - Google Patents
Compuestos de captura de aldehído y usos de los mismosInfo
- Publication number
- CO2019001625A2 CO2019001625A2 CONC2019/0001625A CO2019001625A CO2019001625A2 CO 2019001625 A2 CO2019001625 A2 CO 2019001625A2 CO 2019001625 A CO2019001625 A CO 2019001625A CO 2019001625 A2 CO2019001625 A2 CO 2019001625A2
- Authority
- CO
- Colombia
- Prior art keywords
- aldehyde
- capture compounds
- aldehyde capture
- hne
- mda
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title 1
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/38—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Psychiatry (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Quinoline Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662378065P | 2016-08-22 | 2016-08-22 | |
| PCT/US2017/047945 WO2018039192A1 (en) | 2016-08-22 | 2017-08-22 | Aldehyde trapping compounds and uses thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CO2019001625A2 true CO2019001625A2 (es) | 2019-04-30 |
Family
ID=61190657
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CONC2019/0001625A CO2019001625A2 (es) | 2016-08-22 | 2019-02-22 | Compuestos de captura de aldehído y usos de los mismos |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20180050989A1 (https=) |
| EP (1) | EP3500256A4 (https=) |
| JP (1) | JP2019532029A (https=) |
| CN (1) | CN109640983A (https=) |
| AU (1) | AU2017317524A1 (https=) |
| CA (1) | CA3032521A1 (https=) |
| CO (1) | CO2019001625A2 (https=) |
| MX (1) | MX2019001722A (https=) |
| WO (1) | WO2018039192A1 (https=) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1888548E (pt) | 2005-05-26 | 2012-10-30 | Neuron Systems Inc | Derivado de quinolina para o tratamento de doenças da retina |
| WO2011072141A1 (en) | 2009-12-11 | 2011-06-16 | Neuron Systems, Inc. | Compositions and methods for the treatment of macular degeneration |
| CA2898631C (en) | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| CN118724806A (zh) * | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| CA3016759A1 (en) | 2016-02-28 | 2017-08-31 | Aldeyra Therapeutics, Inc. | Treatment of allergic eye conditions with cyclodextrins |
| US11129823B2 (en) | 2016-05-09 | 2021-09-28 | Aldeyra Therapeutics, Inc. | Combination treatment of ocular inflammatory disorders and diseases |
| MX2019010576A (es) | 2017-03-16 | 2019-10-07 | Aldeyra Therapeutics Inc | Compuestos polimorficos y usos de los mismos. |
| JP7311162B2 (ja) | 2017-10-10 | 2023-07-19 | アルデイラ セラピューティクス， インコーポレイテッド | 炎症性障害の処置 |
| WO2020028820A1 (en) | 2018-08-03 | 2020-02-06 | Aldeyra Therapeutics, Inc. | Topical compositions and methods of preparation and use |
| WO2020033344A1 (en) | 2018-08-06 | 2020-02-13 | Aldeyra Therapeutics, Inc. | Polymorphic compounds and uses thereof |
| EP3856478A4 (en) | 2018-09-25 | 2022-06-08 | Aldeyra Therapeutics, Inc. | FORMULATIONS FOR THE TREATMENT OF DRY EYE |
| US12091388B2 (en) | 2018-12-12 | 2024-09-17 | Teva Pharmaceuticals International Gmbh | Solid state forms of Reproxalap |
| US11786518B2 (en) | 2019-03-26 | 2023-10-17 | Aldeyra Therapeutics, Inc. | Ophthalmic formulations and uses thereof |
| US12098132B2 (en) | 2019-05-02 | 2024-09-24 | Aldeyra Therapeutics, Inc. | Process for preparation of aldehyde scavenger and intermediates |
| CN113784954A (zh) * | 2019-05-02 | 2021-12-10 | 奥尔德拉医疗公司 | 多晶型化合物和其用途 |
| CA3159453A1 (en) * | 2019-12-30 | 2021-07-08 | Huijun YIN | Tricyclic compound, and preparation method therefor and medical use thereof |
| EP4135697A4 (en) * | 2020-04-13 | 2024-05-15 | Aldeyra Therapeutics, Inc. | Quinoline compounds for treating lung, liver, and kidney diseases, disorders, or conditions |
| CA3175856A1 (en) | 2020-05-13 | 2021-11-18 | Todd Brady | Pharmaceutical formulations and uses thereof |
| US20230228744A1 (en) * | 2020-06-04 | 2023-07-20 | Aldeyra Therapeutics, Inc. | Dry eye disease biomarkers and their use for treatment |
| CN114981275B (zh) * | 2020-12-29 | 2023-12-19 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
| CN115843293B (zh) * | 2021-06-25 | 2025-01-24 | 中国医药研究开发中心有限公司 | 三环化合物及其制备方法和医药用途 |
| WO2023192372A1 (en) * | 2022-03-29 | 2023-10-05 | Aldeyra Therapeutics, Inc. | Methods of treating sjögren-larssen syndrome |
| WO2025140390A1 (zh) * | 2023-12-28 | 2025-07-03 | 珠海联邦制药股份有限公司 | Rasp抑制剂在制备治疗或预防慢性咳嗽、哮喘及酒精性肝病疾病的药物中的应用 |
| CN120607478A (zh) * | 2024-03-06 | 2025-09-09 | 深圳湾实验室 | 预防和治疗醛代谢紊乱引起的相关疾病的化合物及其用途 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1888548E (pt) * | 2005-05-26 | 2012-10-30 | Neuron Systems Inc | Derivado de quinolina para o tratamento de doenças da retina |
| RU2015120478A (ru) * | 2012-12-20 | 2017-01-25 | Альдейра Терапьютикс, Инк. | Пери-карбинолы |
| CA2898631C (en) * | 2013-01-23 | 2023-06-13 | Aldeyra Therapeutics, Inc. | Toxic aldehyde related diseases and treatment |
| KR101646666B1 (ko) * | 2015-03-26 | 2016-08-08 | 엘지이노텍 주식회사 | 발광 소자, 이 소자를 포함하는 발광 소자 패키지, 및 이 패키지를 포함하는 조명 장치 |
| CN118724806A (zh) * | 2015-08-21 | 2024-10-01 | 奥尔德拉医疗公司 | 氘化化合物和其用途 |
| KR20180073553A (ko) * | 2015-08-21 | 2018-07-02 | 알데이라 테라퓨틱스, 아이엔씨. | 알데히드 접합체 및 이의 용도 |
-
2017
- 2017-08-22 JP JP2019510396A patent/JP2019532029A/ja active Pending
- 2017-08-22 EP EP17844261.2A patent/EP3500256A4/en not_active Withdrawn
- 2017-08-22 CA CA3032521A patent/CA3032521A1/en not_active Abandoned
- 2017-08-22 WO PCT/US2017/047945 patent/WO2018039192A1/en not_active Ceased
- 2017-08-22 MX MX2019001722A patent/MX2019001722A/es unknown
- 2017-08-22 US US15/682,955 patent/US20180050989A1/en not_active Abandoned
- 2017-08-22 CN CN201780051309.5A patent/CN109640983A/zh active Pending
- 2017-08-22 AU AU2017317524A patent/AU2017317524A1/en not_active Abandoned
-
2019
- 2019-02-22 CO CONC2019/0001625A patent/CO2019001625A2/es unknown
- 2019-04-04 US US16/374,845 patent/US20200062712A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| CN109640983A (zh) | 2019-04-16 |
| WO2018039192A1 (en) | 2018-03-01 |
| US20200062712A1 (en) | 2020-02-27 |
| US20180050989A1 (en) | 2018-02-22 |
| EP3500256A1 (en) | 2019-06-26 |
| EP3500256A4 (en) | 2020-01-08 |
| MX2019001722A (es) | 2019-07-04 |
| CA3032521A1 (en) | 2018-03-01 |
| JP2019532029A (ja) | 2019-11-07 |
| AU2017317524A1 (en) | 2019-02-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2019001625A2 (es) | Compuestos de captura de aldehído y usos de los mismos | |
| CO2018002841A2 (es) | Conjugados de aldehído y usos de los mismos | |
| CL2018000463A1 (es) | Compuestos deuterados y usos de los mismos | |
| MX383535B (es) | Terapias para el tratamiento de enfermedades asociadas con la toxicidad del aldehído. | |
| ECSP19015192A (es) | Composiciones y métodos de inhibir masp-3 para el tratamiento de diversas enfermedades y trastornos | |
| AR132544A2 (es) | ANTICUERPOS PEPTÍDICOS b AMILOIDE ANTI-N3pGlu Y USOS DE LOS MISMOS | |
| ECSP20030074A (es) | Nuevos profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| DOP2019000187A (es) | Compuestos de 5-metil-1,2,4-oxadiazol-3-ilo | |
| GT201600233A (es) | Compuestos y composiciones como agonistas del receptor tipo toll 7 | |
| CR20190311A (es) | Composiciones para tratar afecciones inflamatorias | |
| MX388385B (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| MX2018013472A (es) | Tratamiento de combinacion de trastornos y enfermedades inflamatorios oculares. | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| DOP2016000194A (es) | 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer | |
| AR093705A1 (es) | Depsipeptido y sus usos | |
| MX2017009849A (es) | Composiciones de profármaco de monometilfumarato. | |
| MX2019001634A (es) | Compuestos amidas, composiciones farmacéuticas de estos y métodos para utilizarlos. | |
| MX2016007803A (es) | Composiciones de acidos grasos omega 3 para tratar enfermedades que implican daños al sistema nervioso. | |
| EA201691567A1 (ru) | Способы лечения легких травм головного мозга | |
| CO2019004131A2 (es) | Glicinato de metformina, composiciones farmacéuticas que comprenden la misma, y métodos de uso de la misma | |
| UY37729A (es) | NUEVOS COMPUESTOS QUE INHIBEN LA ACTIVIDAD DE Nav1.7 | |
| MX2019000982A (es) | Compuestos y composiciones y usos de los mismos. | |
| MX2020005952A (es) | Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos. | |
| MX2015008538A (es) | Composicion que comprende un extracto purificado que se aisla de pseudolysimachion rotundum var. subintegrum que contiene una cantidad abundante de ingrediente activo o los compuestos aislados del mismo, como un ingrediente activo para prevenir o tratar enfermedad pulmonar obstructiva cronica y su uso. | |
| MX2017003016A (es) | Derivados de piridazinona como inhibidores de las fosfoinositido-3-cinasas. |